Veracyte (VCYT) | Stock Overview & Key Data
Veracyte Performance Comparison
Stock Range
Today's Range
Low: $23.79
High: $24.63
on July 30, 2025
52 Week Range
Low: $19.73
High: $47.32
on August 5, 2024
on January 30, 2025
All-Time High: $86.03 on February 8, 2021
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$1.9B
EPS
0.42
P/E Ratio (TTM)
57.07
Forward P/E
59.93
P/B Ratio
1.57
PEG Ratio
59.93
Div. Yield
N/A
ROE
2.86%
Beta
2.073
Debt to Equity
4.23
Financial Highlights
Profitability
Gross Margin
69.46%
Operating Margin
7.03%
Profit Margin
7.13%
Returns and Earnings
Return on Assets (TTM)
1.94%
Return on Equity (TTM)
2.86%
EBITDA
$53.0M
Net Income (TTM)
$33.0M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$5.96
Quarterly Revenue Growth (YoY)
18.20%
Quarterly Earnings Growth (YoY)
18.20%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Veracyte VCYT | 1.88B Small-cap | -0.99% | -11.32% | -21.41% | -48.05% | -40.73% | 10.97% | -14.09% | -25.90% |
| Thermo Fisher TMO | 182.58B Large-cap | 2.26% | 17.71% | 11.25% | -21.34% | -8.67% | -22.48% | -19.14% | 15.19% |
| Danaher DHR | 145.32B Large-cap | 3.08% | 3.27% | 2.34% | -8.56% | -11.24% | -26.29% | -20.65% | 12.03% |
| Grail GRAL | 1.38B Small-cap | -17.39% | -34.33% | -2.09% | 7.17% | 88.45% | 103.56% | 130.98% | 130.98% |
| Neogen NEOG | 1.18B Small-cap | -7.11% | -1.67% | -6.93% | -59.06% | -60.64% | -71.31% | -78.06% | -88.52% |
| Opko Health OPK | 1.06B Small-cap | -6.29% | 1.52% | -2.90% | -11.26% | -7.59% | -0.74% | -41.23% | -76.20% |
Ownership & Short Interest
Insider Ownership
0.54%
Institutional Ownership
107.57%
Shares Short
6M
Short Ratio
6.38
Short % of Shares Outstanding
8.71%
Average 10-Day Volume
3M
Average 90-Day Volume
2M
Veracyte Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Veracyte would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is VCYT's 52-week high and low?
- In the last 52 weeks, Veracyte reached a high of $47.32 (on January 30, 2025) and a low of $19.73 (on August 5, 2024).
- What is the market cap and P/E ratio for VCYT?
- Curious about Veracyte's size and valuation? Its market capitalization stands at 1.88B. When it comes to valuation, the P/E ratio (trailing twelve months) is 57.07, and the forward P/E (looking ahead) is 59.93.
- Does VCYT pay dividends? If so, what's the yield?
- As for dividends, Veracyte isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Veracyte's main competitors or similar companies to consider before investing?
When looking at Veracyte, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Thermo Fisher
TMO182.58B Healthcare Diagnostics & Research -22.48% -19.14% Danaher
DHR145.32B Healthcare Diagnostics & Research -26.29% -20.65% Grail
GRAL1.38B Healthcare Diagnostics & Research 103.56% 130.98% Neogen
NEOG1.18B Healthcare Diagnostics & Research -71.31% -78.06% Opko Health
OPK1.06B Healthcare Diagnostics & Research -0.74% -41.23% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Veracyte Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Veracyte's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 2.86%, the Debt to Equity ratio from the most recent quarter is 4.23, and its Gross Profit Margin stands at 69.46%.
- What is the recent revenue and earnings growth for VCYT?
- Looking at Veracyte's growth, its revenue over the trailing twelve months (TTM) was $463M. Compared to the same quarter last year (YoY), quarterly revenue grew by 18.20%, and quarterly earnings saw a YoY growth of 18.20%.
- How much of VCYT stock is held by insiders and institutions?
- Wondering who owns Veracyte stock? Company insiders (like executives and directors) hold about 0.54% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 107.57%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.